Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for acute and chronic neurological disorders that lack adequate therapeutic options.

Our therapies address cellular imbalances related to mitochondrial dysfunction and have been shown to protect neurons in models of chronic neurological diseases and improve cellular recovery in acute neurological injury. We are partnering with internationally renowned scientists in biomedical research in a concerted effort to improve the lives of millions.

leadership
team

Team Member
Greg Archambeau
President
Team Member
Bert van den Bergh
Executive Chairman of the Board
Team Member
Jordan Dubow, MD
Chief Medical Officer
Team Member
Supurna Ghosh, PhD
Vice President of Translational Medicine
Team Member
Andreas Kalmes, PhD
Vice President of Drug Development
Team Member
Brian Polzak
Executive Business Advisor
Team Member
Neil Price
Vice President of Finance

BOARD
of directors

Bert van den Bergh
Executive Chairman of the Board
H. Christian Fibiger, PhD
Board Director, Science and Technology Committee Chairperson
William R. Gallacher
Board Director
Matt Ireland
Board Director, Finance Committee Chairperson
James A. Nordstrom
Board Director
Eric Russell
Board Director, Revalesio Founder
Jane Taylor
Board Director, Governance Committee Chairperson

Science and business
advisory board

Bert van den Bergh
Executive Chairman of the Board
H. Christian Fibiger, PhD
Former VP of Neuroscience for Amgen and Lilly
Lee Brettman, MD
Former CMO of Millennium Pharmaceuticals
Brian Polzak
Executive Business Advisor
Michel Vounatsos
Former CEO of Biogen

Partnership
opportunities

We are always interested in collaborating with like-minded organizations and individuals who can accelerate our path to impacting people who suffer a stroke and those living with ALS. If you would like to explore a potential partnering arrangement with Revalesio, please contact us.
To learn more, connect with us

Contact us

Want to know more about our company, technology, products or potential partnership opportunities?

You can
reach us at